BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Novavax, Inc. (NVAX) said its partner SK bioscience has received expanded manufacturing and marketing approval from the Korean Ministry of Food and Drug Safety for Nuvaxovid for use as a booster for active immunization to prevent COVID-19 in adults aged 18 and older. The approval is based on data from Novavax' Phase 2 trial conducted in the U.S. and Australia, from a separate Phase 2 trial conducted in South Africa, and from the United Kingdom-sponsored COV-BOOST trial.
Novavax' COVID-19 vaccine is authorized for use as an adult booster in more than 35 countries. In Korea, SK bioscience signed a licensing agreement with Novavax and is manufacturing drug substance and drug product of Nuvaxovid for domestic use.
For More Such Health News, visit rttnews.com.
Copyright(c) 2023 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2023 AFX News
